stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

TransMedics Group, Inc.

United States · NASDAQ: TMDX · Market cap: · P/E: · P/S:

TransMedics makes machines that keep donor organs alive and functioning outside the body so they can be transplanted into patients who need them.

TransMedics sells machines and services that keep donated hearts, lungs, and livers alive outside the body. When someone dies and their family donates an organ, that organ normally has to be packed in ice and rushed to a patient within a few hours before it starts to die. TransMedics' Organ Care System does something different: it pumps warm, oxygen-rich blood through the organ and keeps it working, like a tiny portable life-support unit, so doctors can watch the organ, test it, and travel farther to find the right patient. The company sells the hardware to transplant hospitals and also earns money from the disposable supplies and service each time the machine is used.

TransMedics Group, Inc. (TMDX) Organ Care System: line art illustration of a portable Organ Care System cart with a lung in a clear chamber
Organ Care System
The Organ Care System keeps a donor lung warm and breathing outside the body.

The pitch to hospitals is straightforward. A heart or lung kept in a box lets a surgeon assess it before committing to a transplant, and an organ that stays healthier can travel longer distances. That opens up more potential donors and more time to match an organ with the sickest patient. TransMedics sells to transplant centers, mostly large academic hospitals, and it faces competition from older cold-storage methods and rival perfusion products, plus the plain reality that its machines are expensive and every transplant hospital makes its own purchasing decision. The company's growth story has been about moving beyond just selling boxes. It built a national network of planes, trucks, and trained teams to pick up organs and deliver them, and it acquired an aviation company to run that logistics itself. That turned TransMedics from a device maker into an organ-transport service, which is a bigger and harder business but captures more of each transplant. Revenue has grown fast as more hospitals adopted its technology, though heavy spending on that network has kept profits thin and the stock has swung sharply on execution and reimbursement worries.


The bet is that better organ care means more transplants, and more transplants mean more use of TransMedics' machines and supplies. It is a small company taking on a big, slow-moving medical system, which makes it exciting and risky in roughly equal measure.

Saved answer · last researched 16 Nov 2026